Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 11, 2010, Pages 756-760

  Kuoppamaki M ^a,b   Sauramo, A ^a   Korpela, K ^a   Vahteristo, M ^a   Kailajarvi M ^c   Lehtinen, T ^c   Ellmen J ^a  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Clinical Research Services Turku   (Finland)

Author keywords

Controlled release; Dosing; Entacapone; Levodopa; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; STALEVO 200; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NIGHT; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 78649288170     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48756     Document Type: Article

References (18)

1. Ahtila S, Kaakkola S, Gordin A, Korpela K, Heinävaara S, Karlsson M et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa ofter administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol. 1995; 18: 46-57.
2. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005; 20: 224-230. (Pubitemid 40361128)
3. Chaudhuri KR. The basis for day and night-time control of symptoms of Parkinson's disease. Eur J Neurol. 2002; 9 (Suppl): 40-43.
4. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006; 5: 235-245.
5. Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson's disease. Age Ageing. 2006; 35: 220-228.
6. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009; 24: 541-550.
7. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008; 79: 368-376.
8. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 1994; 44: 77-80. (Pubitemid 24029433)
9. Keränen T, Gordin A, Harjola V-P, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993; 16: 145-156.
10. Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered fouror five-times daily. Eur J Clin Pharmacol. 2009; 65: 443-455.
11. Lees AJ, Blackburn NA, Campbell VL. The night-time problems of Parkinson's disease. Clin Neuropharmacol. 1988; 11: 512-519.
12. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Garter JH, Gancher ST, Hammerstad JP. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994; 44: 913-919.
13. Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004; 61: 1563-1568. (Pubitemid 39350267)
14. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997; 42: 747-755.
15. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000; 68: 589-594.
16. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002; 105: 245-255. (Pubitemid 34407226)
17. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt study group. Neurology. 1998; 51: 1309-1314.
18. Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep problems and day-time sleepiness in Parkinson's disease. Mov Disord. 2008; 23: 35-41.